Sunshine Biopharma Secures Shareholder Approval for Series D Warrant Adjustments
Bitget2026/10/27 16:16- Sunshine Biopharma secured shareholder written consent on October 13, 2026, for Series D Warrant provisions.
- The consent authorizes issuance exceeding 20% of outstanding common shares at a deemed discount to the Nasdaq Minimum Price.
- The October 26 reverse split triggers a one-time Series D Warrant adjustment, with a minimum exercise price of $5.50.
- The board may also voluntarily reduce Series D Warrant exercise prices, subject to Nasdaq rules.
- The provisions become effective 20 days after the information statement is mailed, scheduled for about October 30.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Crypto prices
More
